On the evening of June 21st, Sansure Biotech issued an announcement that the company signed the "Investment Agreement" with GeneMind Biosciences Co., Ltd., its shareholders Shenzhen Zhongkedari Gene Technology Co., Ltd., Shenzhen Sanduoshi Industrial Co., Ltd. and Shenzhen Wanlituo Electronic Commerce Technology Co., Ltd. Sansure Biotech acquired a 14.77% equity interest in GeneMind Biosciences through equity transfer and subscription of newly added registered capital at a cost of RMB 255.2 million. Sansure Biotech will complete the transaction with its own funds. When the transaction is completed, Sansure Biotech will become the second largest shareholder of GeneMind Biosciences.

According to the official website of GeneMind Biosciences, the company, headquartered in Shenzhen, focuses on the research and development of the DNA sequencer: the core instrument of the modern molecular diagnostic platform, and is one of the few companies in the world that possess core DNA sequencing technologies and independent products.

Sansure Biotech stated that this strategic investment in GeneMind Biosciences is another important measure taken by the company to improve the universal and full-scenario ecosystem of molecular diagnostic applications and strengthen the platform building, especially to enhance the company's core competitiveness in the field of gene sequencing.

Sansure and GeneMind reached a strategic cooperation: the two parties can give full play to the synergy effect in intellectual property, talent team, technology platform, etc., and complement each other. Sansure will have priority to obtain the global agent of GeneMind's gene sequencer series products.

Technology to break the monopoly of importing gene sequencers

Gene sequencers are in the upstream of the gene sequencing industry chain. For a long time, the upstream gene sequencing platform based on gene sequencers has been monopolized by a few European and American companies. This field has significant high-tech barriers, long R&D cycles, and high interdisciplinary characteristics, and the local research and development started late in China.

However, GeneMind Biosciences has launched independent innovative research and development of single-molecule sequencing platform GenoCare and high-throughput sequencing platform GenoLab, which can provide "instrument-reagent-chip-software" full platform solutions. Among them, GenoCare is the first domestic single-molecule sequencer to obtain the EU CE certification in China.

To improve the ecosystem of the industrial chain

To accelerate the creation of a platform-based enterprise

It is reported that Sansure began to deploy the field of high-throughput gene sequencing in 2013, and has built a bioinformatics and high-throughput gene sequencing team of nearly 100 people, built leading technology platforms, and developed tumor screening, a series of clinical and scientific research testing service items such as companion diagnosis of individualized tumor medication, metagenomic testing of pathogenic microorganisms, non-invasive prenatal screening, and chronic disease management. The gene sequencing platform independently developed by GeneMind and the current core technology platform of Sansure Biotech belong to the field of molecular diagnostics, and have good technical capabilities complementary.

Sansure Biotech will further improve the company’s industrial chain layout and build a comprehensive molecular diagnostic technology platform integrating PCR, gene chip, gene sequencing, mobile molecular diagnosis, biological information, etc., so that it can build more complete solutions and accelerate innovation molecular diagnostic technology platform-type enterprise with capability and high industrial conversion efficiency.